1365964-60-8

Basic information

• Product Name: 2-(6-broMoH-iMidazo[1,2-a]pyridin-2-yl)ethanaMine dihydrochloride
• Synonyms: 2-(6-broMoH-iMidazo[1,2-a]pyridin-2-yl)ethanaMine dihydrochloride;6-Bromoimidazo[1,2-a]pyridine-2-ethanamine hydrochloride;2-(6-BROMOH-IMIDAZO[1,2-A]PYRIDIN-2-YL)ETHANAMINE 2HCL
• CAS NO: 1365964-60-8
• Molecular Formula: C8H12BrCl2N3O
• Molecular Weight: 317.01038
• Mol File: 1365964-60-8.mol
• Article Data: 2

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 2-(6-broMoH-iMidazo[1,2-a]pyridin-2-yl)ethanaMine dihydrochloride(CAS DataBase Reference)
• NIST Chemistry Reference: 2-(6-broMoH-iMidazo[1,2-a]pyridin-2-yl)ethanaMine dihydrochloride(1365964-60-8)
• EPA Substance Registry System: 2-(6-broMoH-iMidazo[1,2-a]pyridin-2-yl)ethanaMine dihydrochloride(1365964-60-8)

Safety Data

• Hazardous Substances Data: 1365964-60-8(Hazardous Substances Data)

Usage

Type of Compound

A chemical compound used in chemical research and drug development

Derivative

Ethanamine derivative

Group

Contains a bromoimidazopyridine group

Potential Applications

Development of therapeutic agents for various medical conditions

Chemical Structure

Valuable for study and potential use in pharmacology and medicinal chemistry

Form

Dihydrochloride salt

Benefits of Dihydrochloride Form

Enhanced solubility and stability, making it more suitable for laboratory settings and drug formulation

Upstream product

• 1403658-76-3 2-[2-(6-bromoimidazo[1,2-a]pyridin-2-yl)ethyl]-1Hisoindole-1,3(2H)-dione 
• 1072-97-5 5-bromo-2-pyridylamine 

Downstream Products

• 1428761-49-2 N,N-diethyl-2-[6-(phenylsulfonyl)imidazo[1,2-a]-pyridin-2-yl]ethanamine 
• 1428761-52-7 8-bromo-2-ethyl-1,2,3,4-tetrahydro-1-methyldipyrido[1,2-a:4',3'-d]imidazole 
• 1428761-45-8 2-(6-bromo-1H-imidazo[1,2-a]pyridin-2-yl)-N,N-diethylethanamine 

Relevant articles and documents

Exploring 6-(substituted sulfonyl)imidazopyridines as a potential scaffold for the design of 5-HT6 ligands

Cognitive dysfunction is a characteristic of various forms of dementia such as Alzheimer's disease. We have focused on the 5-HT6 receptor in order to identify potent ligands. Herein we report the design of a novel series of 6-sulfonylimidazole derivatives substituted with an alkylamino chain at the 2- or 3-position, their synthesis, and their ability to interact with 5-HT 6 receptors as evaluated in radioligand binding assays.